Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management will participate in a panel discussion at the virtual Cantor Fitzgerald Rare Orphan Disease Summit on March 29, 2022.
Adi Mor, PhD, co-founder and Chief Scientific Officer of Chemomab, will participate in the panel.
Cantor Fitzgerald Rare Orphan Disease Summit (virtual)
Panel: Platforms and Pipelines in a Product: How One Concept Could Have Multiple Applications Across Rare Diseases
Presenter: Dr. Adi Mor, Chemomab co-founder and Chief Scientific Officer
Date: March 29, 2022
Time: 9:00 am – 10:15 am ET
Please reach out to your Cantor Fitzgerald representative to access the Rare Orphan Disease Summit.
About Chemomab Therapeutics Ltd.
Chemomab is a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is currently in two Phase 2 clinical trials—one in primary sclerosing cholangitis and the second in liver fibrosis, with a Phase 2 trial in systemic sclerosis expected to begin in 2022. For more information on Chemomab, visit www.chemomab.com.
Contacts:
Investor Relations: | Media: |
Irina Koffler | Barbara Lindheim |
LifeSci Advisors, LLC | Chemomab Therapeutics |
Phone: +1-917-734-7387 | Consulting Vice President |
This email address is being protected from spambots. You need JavaScript enabled to view it. | Investor & Public Relations, |
Strategic Communications | |
Phone: +1-917-355-9234 | |
This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$1.11 |
| Daily Change: | -0.05 -4.31 |
| Daily Volume: | 42,084 |
| Market Cap: | US$20.930M |
March 06, 2025 March 03, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
